Viewing nowLyrica Capsule 75mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Korea HuTex Pharmaceuticals Co., Ltd.

MFDS item code 201600253 · Approved 2016.01.14 · Insurance code 649102940
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy. It is effective in treating fibromyalgia. Therefore, it helps improve symptoms of neuropathic pain, seizures, and myalgia.
Administer the total daily dose of this medicine, pregabalin, orally in 2 divided doses, with or without food. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose TID = Divide the total daily dose into 3 doses BID = Divide the total daily dose into 2 doses QD = Administer once daily a: The total daily dose (mg/day) should be divided as specified in the administration regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behavior, so if there are changes in mood or symptoms of depression during use, consult a doctor immediately. Individuals allergic to pregabalin or any of its components should not take this medicine. Patients with lactose intolerance or specific genetic metabolic disorders should also avoid this medication. Diabetic patients should be cautious as weight gain may require adjustment of blood sugar control medications. If severe allergic reactions such as angioedema occur, stop taking and inform healthcare providers immediately. Elderly individuals may experience dizziness, drowsiness, or confusion after taking this medication, so they should use it with caution. Some patients may experience blurred vision or changes in eyesight, so inform a doctor if any of these symptoms occur. Suddenly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so dosage should be gradually reduced according to medical advice. Patients with a history of drug abuse should be cautious as this medication may have a high risk of abuse; report any unusual behavior immediately. Patients with impaired renal function may require dosage adjustments. Patients with heart disease should also exercise caution when taking this medication. Concomitant use with other CNS depressants or alcohol may increase the risk of drowsiness or respiratory depression; caution is advised. During early pregnancy, there may be a risk of fetal malformations, so pregnant women should avoid this medication, and women of childbearing age should use effective contraception. Breastfeeding women should discuss with their doctor whether to stop breastfeeding or discontinue this medication as it can be passed into breast milk. Avoid driving or operating hazardous machinery while taking this medication for safety. Severe skin reactions may occur, and if symptoms such as rashes or blisters occur, stop taking this medication immediately. In case of overdose, symptoms like drowsiness, confusion, and seizures may appear, requiring immediate medical attention. Children, elderly patients, and those with impaired renal function should exercise particular caution when taking this medication. This medication should be kept out of the reach of children and caution should be taken not to transfer it to other containers as it may change the quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is recommended to maintain a storage temperature between 15 degrees and 30 degrees Celsius. This helps maintain the medication's efficacy and safety for a longer time.
A hard capsule with a light brown upper part and a white lower part containing a white powder that is white to pale yellow in color.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Korea HuTex Pharmaceuticals Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.